ProQR Therapeutics NV (NASDAQ:PRQR)
| 6.25 BATS BZX Real-Time Price As of 3:56pm ET |  -0.12 / -1.88%Today’s Change | 4.05 Today|||52-Week Range 9.46 | -21.97% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $480.3M |
Company Description
ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Its product pipeline include Sepofarsen, QR-421a, QR-1123, and QR-504a. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer, and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.
Contact Information
ProQR Therapeutics NV Zernikedreef 9 Leiden Zuid-holland 2333 CK |
Employees
Shareholders
| Other institutional | 38.29% |
| Mutual fund holders | 26.23% |
| Individual stakeholders | -- |
Top Executives
| Daniel Anton de Boer | Chief Executive Officer |
| Smital Shah | Chief Financial & Business Officer |
| Aniz Girach | Chief Medical Officer |
| Jennifer Pluim | Vice President-Medical Affairs |
| Naveed K. Shams | Chief Scientific Officer |
